New cancer drug H1710 enters first human tests

NCT ID NCT06992713

Recruiting now Disease control Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any early signs that the drug might help control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: H1710 (an experimental drug given by injection)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may not shrink tumors or could cause side effects. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, 100142, China
Jiangsu Province Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210029, China
Peking University Shougang Hospital
RECRUITING

Beijing, 100144, China
Shanghai East Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.